obinutuzumab

AssetAntibody

Anti-CD20 monoclonal antibody that depletes B cells

Stage
Phase 3
Modality
Antibody
Target
Inflammation
Indications
1
Trials
1
Developers
1

Indications

1
  • Targets and what it contains2
  • Owner and partners1
  • Trials1
  • Evidence for its targets1
  • Competitors4

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Updated 7 Oct 2026 · 1 source

Assets